Mayank Verma, M.D., Ph.D. Titles and Appointments Assistant Professor Schools Medical School Departments Pediatrics You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Mayank Verma, M.D., Ph.D., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center. Dr. Verma earned his medical degree and a doctorate in integrative biology and physiology at the University of Minnesota Medical School. He completed his residency in child neurology at UT Southwestern Medical Center and then served as a pediatric neurology fellow in the Minassian Lab. He completed a research fellowship in gene therapy as part of his child neurology basic neuroscience pathway under Berge Minassian, M.D. Dr. Verma joined the UT Southwestern faculty in 2025. He is a physician-scientist who is involved in preclinical and translational studies focusing on progressive myoclonic epilepsy and glycogen storage disorders. His lab studies progressive myoclonic epilepsy and neuronal glycogen storage disorders, which are considered rare neurological diseases that have no treatment. As a scientist, he works to translate discoveries from animal models into improved natural history and biomarker studies, with the ultimate goal of developing gene therapy clinical trials and the tools needed to effectively treat children with neurological diseases. Dr. Verma’s clinical focus includes pediatric epilepsies, pediatric neuromuscular disorders, and neurogenetic diseases. Dr. Verma has delivered numerous presentations and has published and co-authored many articles, reviews, and book chapters. His professional affiliations include Child Neurology Society. Education Medical School (2025), Medicine Publications Featured Publications Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation. Alao EO, Sheibani M, Wu J, Marriam U, Evans D, Kasiri S, Verma M, Nitschke S, Nitschke F, Gray SJ, Mitra S, Minassian BA, Neurotherapeutics 2026 Mar 23 2 e00866 Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity. Gumusgoz E, Kasiri S, Youssef I, Verma M, Chopra R, Villarreal Acha D, Wu J, Marriam U, Alao E, Chen X, Guisso DR, Gray SJ, Shah BR, Minassian BA, Gene Ther 2025 May 32 3 237-245 Protocol for the three-dimensional analysis of rodent skeletal muscle. Karthikeyan S, Asakura Y, Verma M, Asakura A, STAR Protoc 2025 Mar 6 1 103549 Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease. Nitschke S, Montalbano AP, Whiting ME, Smith BH, Mukherjee-Roy N, Marchioni CR, Sullivan MA, Zhao X, Wang P, Mount H, Verma M, Minassian BA, Nitschke F, EMBO J 2025 Mar 44 5 1379-1413 Three-dimensional imaging studies in mice identify cellular dynamics of skeletal muscle regeneration. Collins BC, Shapiro JB, Scheib MM, Musci RV, Verma M, Kardon G, Dev Cell 2024 Jun 59 11 1457-1474.e5 CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsy. Gumusgoz E, Kasiri S, Verma M, Wu J, Villarreal Acha D, Marriam U, Fyffe-Maricich S, Lin A, Chen X, Gray SJ, Minassian BA, Gene Ther 2024 May 31 5-6 234-241 Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses. Mitra S, Chen B, Shelton JM, Nitschke S, Wu J, Covington L, Dear M, Lynn T, Verma M, Nitschke F, Fuseya Y, Iwai K, Evers BM, Minassian BA, Acta Neuropathol 2024 Feb 147 1 46 VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy. Bosco J, Zhou Z, Gabriëls S, Verma M, Liu N, Miller BK, Gu S, Lundberg DM, Huang Y, Brown E, Josiah S, Meiyappan M, Traylor MJ, Chen N, Asakura A, De Jonge N, Blanchetot C, de Haard H, Duffy HS, Keefe D, Mol Ther Methods Clin Dev 2021 Jun 21 369-381 Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice. Bosnakovski D, Shams AS, Yuan C, da Silva MT, Ener ET, Baumann CW, Lindsay AJ, Verma M, Asakura A, Lowe DA, Kyba M, J Clin Invest 2020 May 130 5 2465-2477 Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy. Verma M, Shimizu-Motohashi Y, Asakura Y, Ennen JP, Bosco J, Zhou Z, Fong GH, Josiah S, Keefe D, Asakura A, PLoS Genet 2019 Dec 15 12 e1008468 Results 1-10 of 23 1 2 3 Next Last Books Featured Books Unverricht Lundborg Disease. In Handbook of Pediatric Epilepsy Case Studies, Second Edition Verma M, Minassian BA, Andrade DM (2023). Boca Raton, CRC Press
